Achieving glycemic control is important in preventing to prevent long-term type 1 diabetes complications. In this featured study, researchers investigate the use of hybrid closed-loop automated basal insulin delivery system.
Imeglimin is the first in class tetrahydrotriazine‐containing oral glucose-lowering agent
Imeglimin is first in a new class of oral antidiabetic agents. In this featured phase 3 trial from France, researchers describe outcomes 107 patients with type 2 diabetes.
Researchers observed detectable changes in brain volumes and cognitive scores that persist over time in children with early-onset type 1 diabetes.
Study authors performed a retrospective review of a thyroid cancer cohort to evaluate the association between metabolic health and severity of thyroid cancer.
Adopting an anti-inflammatory and low insulinemic diet of green leafy vegetables, full-fat dairy, wine, and coffee instead of red meat, processed meat, nonfatty fish, sugar-sweetened beverages, and refined grains, may reduce T2D risk in postmenopausal women.
For COVID-19 patients without a previous diagnosis of diabetes, fasting blood glucose ≥7.0 mmol/L is an independent predictor of 28-day mortality.
COVID-19 is associated with hyperglycemic emergencies, particularly in patients with existing type 2 diabetes and of African ethnicity.
Review authors summarized preliminary research on COVID-19 and past research on SARS-CoV-1 regarding their relationship with endocrine dysfunction.
Researchers developed a clinical tool to identify patients at risk for persistent abnormal glucose levels during hospitalization.
Presentation patterns are similar in patients with type 1 diabetes admitted with confirmed or suspected COVID-19.
